Asia Firms Tweak Strategy Amid Biosimilars ‘Stampede’
This article was originally published in PharmAsia News
More biosimilar approvals for Asian firms in western markets, building on the success of major players like Celltrion and Samsung, and a shift away from local/regional development strategies, were some of the key trends in the sector highlighted at a recent roundtable in India.
You may also be interested in...
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
A senior executive of Janssen’s supply chain leadership team outlines how the company handled activities in Asia Pacific at the height of the coronavirus outbreak, including ensuring continuous and rapid supplies of critical medicines in China. The company is also prepping against “multiple scenarios” to ensure global access for its potential COVID-19 vaccine.
Expert outlines how pharma can create resilient and secure supply chains and some benefits of localization.